Pharma Exclusives Pressreleases
Valo Health and Novo Nordisk expand collaboration to discover and develop novel treatments for cardiometabolic diseases
Wednesday, January 08, 2025Novo Nordisk AS and Valo Health Inc today announced they have entered into an expanded agreement to discover and develop novel treatments for obesity type diabetes and cardiovascular disease based on Valos extensive human dataset and computation pow...
Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc.
Tuesday, December 31, 2024Immedica Pharma AB Immedica a leading global rare disease company and Marinus Pharmaceuticals Inc a pharmaceutical company committed to improving the lives of patients with seizure disorders today announced that they have entered into an agreement an...
Immunovia discovery study published in top protein research journal
Friday, December 20, 2024Immunovia the pancreatic cancer diagnostics company today announced the peerreviewed publication of the discovery study conducted by Immunovia to identify protein biomarkers for its nextgeneration pancreatic cancer test
Roche’s Phase IIb study of prasinezumab missed primary endpoint, but suggests possible benefit in early-stage Parkinson’s disease
Thursday, December 19, 2024Roche announced today results from the Phase IIb PADOVA study investigating prasinezumab in people with earlystage Parkinsons disease treated for a minimum of months while on stable symptomatic treatment Prasinezumab showed potential clinical effic...
Hansa Biopharma announces positive full results from 15-HMedIdeS-09 Phase 2 study and comparative analysis of imlifidase in patients with Guillain-Barré Syndrome
Wednesday, December 18, 2024Hansa Biopharma announced positive full results from the HMedIdeS single arm Phase study of imlifidase a first in class IgG cleaving enzyme in GuillainBarr Syndrome GBS and an indirect treatment comparison of the HMedIdeS study data to the Internati...
Roche transforms mass spectrometry diagnostics with launch of cobas® Mass Spec solution
Wednesday, December 18, 2024Roche announced today that it has received CE mark approval for its cobas Mass Spec solution including the cobas i analyser and the first Ionify reagent pack of four assays for steroid hormones The CE mark is the first milestone in the global launch...
Lilly and EVA Pharma announce regulatory approval and release of locally manufactured insulin in Egypt
Tuesday, December 17, 2024The Egyptian Drug Authority approved the insulin glargine injection manufactured by EVA Pharma through a collaboration with Eli Lilly and Company Launched in the collaboration aims to deliver a sustainable supply of highquality affordable human and...
Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease
Tuesday, December 17, 2024Teva Pharmaceuticals a US affiliate of Teva Pharmaceutical Industries Ltd and Sanofi today announce that the Phase b RELIEVE UCCD study met its primary endpoints in patients with ulcerative colitis UC and Crohns disease CD RELIEVE UCCD investigated d...
Roche’s Vabysmo prefilled syringe (PFS) approved in the EU for three retinal conditions that can cause blindness
Friday, December 13, 2024Roche announced today that the European Medicines Agency has approved Vabysmo faricimab mg singledose prefilled syringe PFS for use in the treatment of neovascular or wet agerelated macular degeneration nAMD diabetic macular edema DME and macular ed...
Virax Biolabs Announces Agreement with Tebubio to Expand Distribution of ImmuneSelect Across the European Union, Norway, and Switzerland
Wednesday, December 11, 2024Virax Biolabs Group Limited an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases today announced that it has entered into a nonexclusive distribution agreement with French company Tebubio to...
